» Articles » PMID: 27515331

Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction

Abstract

Background: Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial infarctions in experimental models.

Objectives: This study aimed to analyze whether BCM, compared with saline control, would result in less LV dilation and fewer adverse clinical events between baseline and 6 months.

Methods: In an international, randomized, double-blind, controlled trial, 303 subjects with large areas of infarction despite successful primary percutaneous coronary intervention (PCI) of ST-segment elevation myocardial infarction (STEMI) were randomized 2:1 to BCM or saline injected into the infarct-related artery 2 to 5 days after primary PCI. The primary outcome was mean change from baseline in LV end-diastolic volume index (LVEDVI) at 6 months. Secondary outcomes included change in Kansas City Cardiomyopathy Questionnaire score, 6-minute walk time, and New York Heart Association functional class at 6 months. The primary safety endpoint was a composite of cardiovascular death, recurrent MI, target-vessel revascularization, stent thrombosis, significant arrhythmia requiring therapy, or myocardial rupture through 6 months.

Results: In total, 201 subjects were assigned to BCM and 102 to saline control. There was no significant difference in change in LVEDVI from baseline to 6 months between the groups (mean change ± SD: BCM 14.1 ± 28.9 ml/m(2) vs. saline 11.7 ± 26.9 ml/m(2); p = 0.49). There was also no significant difference in the secondary endpoints. The rates of the primary safety outcome were similar between the 2 groups (BCM 11.6% vs. saline 9.1%; p = 0.37).

Conclusions: Intracoronary deployment of BCM 2 to 5 days after successful reperfusion in subjects with large myocardial infarction did not reduce adverse LV remodeling or cardiac clinical events at 6 months. (IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction [PRESERVATION I]; NCT01226563).

Citing Articles

Brown Adipose Stem Cell-Loaded Resilin Elastic Hydrogel Rebuilds Cardiac Function after Myocardial Infarction via Collagen I/III Reorganisation.

Zhao L, Liu H, Gao R, Zhang K, Gong Y, Cui Y Gels. 2024; 10(9).

PMID: 39330170 PMC: 11431146. DOI: 10.3390/gels10090568.


Marine Compounds and Age-Related Diseases: The Path from Pre-Clinical Research to Approved Drugs for the Treatment of Cardiovascular Diseases and Diabetes.

Giuliani M, Bigossi G, Lai G, Marcozzi S, Brunetti D, Malavolta M Mar Drugs. 2024; 22(5).

PMID: 38786601 PMC: 11123485. DOI: 10.3390/md22050210.


Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.

Xu Q, Xiao Z, Yang Q, Yu T, Deng X, Chen N Mater Today Bio. 2024; 25:100978.

PMID: 38434571 PMC: 10907859. DOI: 10.1016/j.mtbio.2024.100978.


Percutaneous Alginate Hydrogel Endomyocardial Injection with a Novel Dedicated Catheter Delivery System: An Animal Feasibility Study.

Wang B, Gao C, Lim S, Wang R, Zhu C, Onuma Y J Cardiovasc Transl Res. 2024; 17(4):842-850.

PMID: 38376702 PMC: 11371841. DOI: 10.1007/s12265-024-10497-8.


A Powerful Tool in the Treatment of Myocardial Ischemia-Reperfusion Injury: Natural and Nanoscale Modified Small Extracellular Vesicles Derived from Mesenchymal Stem Cells.

Zhou Z, Zhang X, Wang S, Wang X, Mao J Int J Nanomedicine. 2024; 18:8099-8112.

PMID: 38164265 PMC: 10758182. DOI: 10.2147/IJN.S443716.